News
XOMAO
25.85
+1.49%
0.38
Weekly Report: what happened at XOMAO last week (0406-0410)?
Weekly Report · 1d ago
Weekly Report: what happened at XOMAO last week (0330-0403)?
Weekly Report · 04/06 09:38
2 Royalty Income Streams You Don't Have To Work For
Seeking Alpha · 03/31 11:35
XOMA Royalty announces annual shareholder meeting via virtual webcast
Reuters · 03/30 21:38
Weekly Report: what happened at XOMAO last week (0323-0327)?
Weekly Report · 03/30 09:38
Weekly Report: what happened at XOMAO last week (0316-0320)?
Weekly Report · 03/23 09:37
XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend
Seeking Alpha · 03/18 20:42
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Barchart · 03/18 15:30
XOMA 2025 income, revenue jump on portfolio expansion, milestone payments
Reuters · 03/18 10:10
XOMA ROYALTY REPORTS 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
Reuters · 03/18 10:00
Weekly Report: what happened at XOMAO last week (0309-0313)?
Weekly Report · 03/16 09:36
XOMA Royalty schedules webcast to discuss fourth-quarter and full-year results
Reuters · 03/12 10:30
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
Barchart · 03/12 05:30
Weekly Report: what happened at XOMAO last week (0302-0306)?
Weekly Report · 03/09 09:38
XOMA ROYALTY CORP: EXPECTS FY2025 CASH RECEIVED FROM ROYALTIES AND MILESTONES TO BE ABOUT $49 TO $50 MLN
Reuters · 03/02 11:21
Weekly Report: what happened at XOMAO last week (0223-0227)?
Weekly Report · 03/02 09:37
XOMA ROYALTY CORP <XOMA.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $50 FROM $45
Reuters · 02/24 11:05
U.S. RESEARCH ROUNDUP-Dollar General, Keysight Technologies, Teledyne Technologies
Reuters · 02/24 07:56
Weekly Report: what happened at XOMAO last week (0216-0220)?
Weekly Report · 02/23 09:36
XOMA Royalty to Present at T.D. Cowen and Leerink Global Healthcare Investor Conferences
Reuters · 02/18 21:30
More
Webull provides a variety of real-time XOMAO stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMAO
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.